JN.1刺突蛋白免疫在叙利亚仓鼠中依免疫史拓宽结合与中和抗体
在先前接种三剂不同新冠疫苗的叙利亚仓鼠中,评估JN.1变异株刺突蛋白纳米颗粒疫苗的免疫原性与效力。JN.1免疫可提升JN.1和KP.2特异性抗体,相对增幅取决于疫苗史且与免疫前JN.1中和滴度负相关;JN.1加强后所有仓鼠均抵抗KP.2攻击,组织感染性病毒滴度平均处于或低于检测限。
要点
- 三剂纳米颗粒S蛋白疫苗诱导持久中和抗体,XBB.1.5疫苗史与JN.1/KP.2中和相关。
- JN.1加强后抗体相对增幅依疫苗史而异,与加强前JN.1中和滴度负相关。
- JN.1加强仓鼠抵抗KP.2攻击,组织感染性病毒滴度平均≤检测限。
核心结论
- 变异株新冠疫苗加强在不同免疫背景下有效,并可保护 against 相关病毒变异株。
研究设计与样本
- 在先前接种三剂Wuhan-1原型、原型+BA.5或XBB.1.5新冠疫苗九个月后的叙利亚仓鼠中评估JN.1变异株刺突蛋白纳米颗粒疫苗。
- 免疫前后收集血清检测针对包括JN.1和KP.2在内的不同SARS-CoV-2变异株抗体应答。
- 年龄匹配的初始仓鼠和JN.1疫苗加强仓鼠经KP.2变异株攻击后检测鼻甲、气管和肺病毒载量。
主要发现
- 三剂纳米颗粒S蛋白疫苗诱导持久病毒中和抗体应答。
- JN.1和KP.2变异株中和与一剂或多剂XBB.1.5疫苗相关。
- JN.1变异株疫苗免疫提升JN.1和KP.2特异性抗体应答,但滴度相对增幅取决于疫苗史且与加强前JN.1中和滴度负相关。
- 攻击后JN.1加强仓鼠无论免疫史或JN.1特异性抗体应答增幅如何均受保护,所有组织感染性病毒滴度平均处于或低于检测限。
- 病毒RNA水平下降与攻击前血清KP.2抗体滴度相关。
临床怎么用
- 在临床与公共卫生决策中,应考虑个体既往新冠疫苗免疫史对变异株疫苗加强后抗体应答幅度的影响。
- 变异株疫苗加强可在多样免疫背景下提供针对相关变异株的攻击保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With much of the world exposed to previous variants of SARS-CoV-2, testing of current COVID-19 vaccines in preclinical models should occur in the context of preexisting immunity to the virus. Here, we evaluated the immunogenicity and efficacy of a JN.1 variant spike (S) protein-based nanoparticle vaccine in Syrian hamsters nine months after three immunizations with Wuhan-1 prototype, prototype + BA.5, or XBB.1.5 variant COVID-19 vaccines. Serum was collected prior to and three weeks after the JN.1 immunization to measure antibody responses to different variants of SARS-CoV-2, including JN.1 and KP.2. To assess efficacy, age-matched naive and JN.1 vaccine-boosted hamsters were challenged with the KP.2 variant of SARS-CoV-2, and viral burden in the nasal turbinates, trachea, and lungs was measured. Three doses of the nanoparticle S protein vaccine induced long-lasting virus neutralizing antibody responses, and neutralization of the JN.1 and KP.2 variants of SARS-CoV-2 was associated with one or more doses of the XBB.1.5 vaccine. Subsequent immunization with the JN.1 variant vaccine boosted JN.1 and KP.2 specific antibody responses, however, the relative increase in titer was dependent on vaccine history and inversely correlated with JN.1 neutralizing titers prior to boosting. Following challenge, JN.1-boosted hamsters, regardless of their immune history or increase in JN.1 specific antibody response, were protected against the KP.2 variant with infectious virus titers averaging at or below the limit of detection in all tissues. The reductions in viral RNA levels correlated with pre-challenge serum antibody titers against KP.2. In conclusion, boosting with a variant SARS-CoV-2 vaccine is effective in a diverse immune landscape and protects against a related virus variant.
引用
- Darling TL, Liang CY, Hastings I, et al. Immunization with JN.1 spike protein increases the breadth of binding and neutralizing antibodies in Syrian hamsters in an immune-history dependent manner. Vaccine. 2026. PMID: 42966039. doi:10.1016/j.vaccine.2026.129310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。